Gencurix Inc. (KOSDAQ:229000)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,593.00
-56.00 (-3.40%)
Mar 28, 2025, 3:30 PM KST
-55.63%
Market Cap 23.99B
Revenue (ttm) 3.39B
Net Income (ttm) -12.55B
Shares Out 15.06M
EPS (ttm) -877.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 28,203
Average Volume 54,471
Open 1,648.00
Previous Close 1,649.00
Day's Range 1,582.00 - 1,662.00
52-Week Range 1,131.00 - 4,150.00
Beta 0.16
RSI 37.11
Earnings Date Mar 21, 2025

About Gencurix

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company was founded in 2011 and is headquartered in Seoul, South Korea. [Read more]

Industry Medical - Specialties
Sector Healthcare
Founded 2011
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 229000
Full Company Profile

Financial Performance

In 2023, Gencurix's revenue was 2.60 billion, an increase of 1.60% compared to the previous year's 2.56 billion. Losses were -19.26 billion, -21.70% less than in 2022.

Financial Statements

News

There is no news available yet.